Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Tumor angiogenesis, the formation of new blood vessels that supply tumors, is a critical process for cancer growth and metastasis.
• The Tie-2 receptor kinase, expressed on vascular endothelium, plays a crucial role in regulating angiogenesis and is a potential therapeutic target.
• Targeting the Tie-2 pathway offers a promising strategy for developing novel anti-cancer therapies by inhibiting tumor vascularization.

Purpose of the Study:

• To investigate the therapeutic potential of blocking the Tie-2 receptor-interaction pathway using a novel adenoviral vector-delivered intrabody.
• To evaluate the efficacy of inhibiting Tie-2 receptor expression on tumor growth and angiogenesis in established human tumor xenografts in mice.
• To determine if the observed anti-tumor effects are specifically mediated by the inhibition of tumor angiogenesis via Tie-2 blockade.

Main Methods:

• An adenoviral vector (pAd-2S03) was engineered to deliver a recombinant single-chain antibody fragment rabbit intrabody targeting both mouse and human Tie-2.
• pAd-2S03 was administered to mice bearing established human Kaposi's sarcoma (SLK) or colon carcinoma (SW1222) xenografts.
• Tumor growth, vessel density (via histopathologic analysis of cryosections), and the effect of a Tie-2 monospecific intrabody (pAd-1S05) were assessed.

Main Results:

• Treatment with pAd-2S03 significantly inhibited the growth of both SLK (75% inhibition) and SW1222 (63% inhibition) tumors compared to controls (P < 0.01).
• Histopathologic analysis revealed a marked decrease (>87%) in tumor vessel density in pAd-2S03 treated mice for both tumor models (P < 0.01).
• A human Tie-2 monospecific intrabody (pAd-1S05) did not affect tumor growth, confirming the anti-tumor effect was due to Tie-2 inhibition and anti-angiogenesis.

Conclusions:

• The Tie-2 receptor pathway is essential for the growth of both Kaposi's sarcoma and colon carcinoma xenografts in murine models.
• Adenoviral delivery of a Tie-2-inhibiting intrabody effectively suppresses tumor angiogenesis and significantly inhibits tumor growth.
• These findings highlight the therapeutic potential of antiangiogenic agents targeting the endothelium-specific Tie-2 receptor for cancer treatment.